During the last session, Avalo Therapeutics Inc (NASDAQ:AVTX)’s traded shares were 73888.0, with the beta value of the company hitting 1.02. At the end of the trading day, the stock’s price was $4.41, reflecting an intraday loss of -4.75% or -$0.22. The 52-week high for the AVTX share is $17.49, that puts it down -296.6 from that peak though still a striking -0.68% loss since the share price plummeted to a 52-week low of $4.44. The company’s market capitalization is $47.06M, and the average intraday trading volume over the past 10 days was 74650.0 shares, and the average trade volume was 73.26K shares over the past three months.
Avalo Therapeutics Inc (AVTX) received a consensus recommendation of Hold from analysts. That translates to a mean rating of 1.29. AVTX has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 2 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -1.61.
Avalo Therapeutics Inc (NASDAQ:AVTX) trade information
Avalo Therapeutics Inc (AVTX) registered a -4.75% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -4.75% in intraday trading to $4.41, hitting a weekly high. The stock’s 5-day price performance is -10.73%, and it has moved by -44.81% in 30 days. Based on these gigs, the overall price performance for the year is -72.33%. The short interest in Avalo Therapeutics Inc (NASDAQ:AVTX) is 0.12 million shares and it means that shorts have 1.11 day(s) to cover.
The consensus price target of analysts on Wall Street is $23, which implies an increase of 80.83% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $23 and $23 respectively. As a result, AVTX is trading at a discount of -421.54% off the target high and -421.54% off the low.
Avalo Therapeutics Inc (AVTX) estimates and forecasts
In the rating firms’ projections, revenue will decrease -100.00% compared to the previous financial year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 56.49%. While earnings are projected to return 78.42% in 2025, the next five years will return 46.00% per annum.
AVTX Dividends
Avalo Therapeutics Inc is due to release its next quarterly earnings on 2025-Mar-19. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Avalo Therapeutics Inc (NASDAQ:AVTX)’s Major holders
Avalo Therapeutics Inc insiders own 6.41% of total outstanding shares while institutional holders control 70.96%, with the float percentage being 75.82%.
Also, the Mutual Funds coming in first place with the largest holdings of Avalo Therapeutics Inc (AVTX) shares are VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund and Fidelity Concord Street Trust-Fidelity Extended Market Index Fund . Data provided on Dec 31, 2024 indicates that VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund owns about 165.8 shares. This amounts to just over 1.55 percent of the company’s overall shares, with a $0.73 million market value. The same data shows that the other fund manager holds slightly less at 51.27, or about 0.48% of the stock, which is worth about $0.23 million.
